|
1) Barrett BJ, Fenton SS, Ferguson B, et al. Clinical practice guidelines for the management of anemia coexistent with chronic renal failure. Canadian Society of Nephrology. J Am Soc Nephrol. 1999; 10 (Suppl 13): S292-6
|
|
|
|
2) NKF-K/DOQI Clinical practice guidelines for anemia of chronic kidney disease: update. Am J Kidney Dis. 2001; 37(Suppl 1): S182-S238
|
|
|
|
|
3) 日本透析医学会. 慢性血液透析患者における腎性貧血治療のガイドライン. 透析会誌. 2004; 37: 1737- 63
|
|
|
|
|
|
4) European best practice guideline㈼ working group. European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant. 2004; 19(Suppl 2): S1-47
|
|
|
|
|
|
5) Pollock C, Voss D, Hodson E, et al. Caring for Australasians with Renal Impairment (CARI). The CARI guidelines. Nutrition and growth in kidney disease. Nephrology. 2005; 10(Suppl 5): S177-230
|
|
|
|
|
|
6) KDOQI Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis. 2006; 47(Suppl 3): S11-85
|
|
|
|
|
|
7) KDOQI Clinical practice guideline and clinical practice recommendations for anemia in chronic kidney disease: 2007 Update of hemoglobin target. Am J Kidney Dis. 2007; 50: 476-530
|
|
|
|
|
|
8) 日本透析医学会統計調査委員会, 編. わが国の慢性透析療法の現況(2005年12月31日現在). 日本透析医学会. 2006
|
|
|
|
|
|
9) 日本透析医学会統計調査委員会, 編. わが国の慢性透析療法の現況(2006年12月31日現在). 日本透析医学会. 2007
|
|
|
|
|
|
10) Hayashi T, Suzuki A, Shoji T, et al. Cardiovascular effect of normalizing the hematocrit level during erythropoietin therapy in predialysis patients with chronic renal failure. Am J Kidney Dis. 2000; 35: 250-6
|
|
|
|
|
|
11) Kuriyama S, Tomonari H, Yoshida H, et al. Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. Nephron. 1997; 77: 176-85
|
|
|
|
|
|
12) 椿原美治, 高元俊彦, 栗山 哲, 他. 保存期慢性腎不全患者に対するエポエチンベータ投与による腎性貧血改善の心機能に及ぼす効果. 腎と透析. 2003; 54: 505-11
|
|
|
|
|
13) 池田俊也, 春木繁一, 椿原美治, 他. 保存期慢性腎不全患者に対するエポエチンベータ投与による貧血改善効果のquality of life(QOL)に及ぼす影響. 腎と透析. 2003; 55: 203-9
|
|
|
|
|
|
14) Kubota M, Hiramitsu M, Yamakawa M, et al and KRN321 Study Group. Target level for hemoglobin correction by darbepoetin alfa(KRN321)for peritoneal dialysis(PD)patients in Japan. Paper presented at: 2007 ASN Congress(SU-PO792), 2007
|
|
|
|
|
|
15) Inaguma D, Tsubakihara Y, Hirakata H, et al. Monthly subcutaneous treatment of darbepoetin alfa(KRN321) could maintain higher Hb safety and have benefical effects on cardiac function of Japanese CKD patients not on dialysis. Paper presented at: 44th ERA-EDTA Congress (SaP353), 2007
|
|
|
|
|
|
16) Akizawa T, Gejyo F, Nishi S, et al; KRN321 Study Group. Taget level for hemoglobin correction by darbepoetin alfa(KRN321) for patients with chronic kidney disease(CKD) not on dialysis in randomaized controlled study; from the viewpoint of the efficacy. Paper presented at: 2007 ASN Congress(SU-PO804), 2007
|
|
|
|
|
|
17) Tubakihara Y, Shoji T, Gejyo F, et al and KRN321 Study Group. Taget level for hemoglobin correction by darbepoetin alfa(KRN321) for patients with chronic kidney disease(CKD) not on dialysis in randomaized controlled study; from the viewpoint of the safety. Paper presented at: 2007 ASN Congress (SU-PO818), 2007
|
|
|
|
|
|
18) Singh A K, Szczech L, Tang K L, et al; CHOIR Investigators. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006; 355: 2085-98
|
|
|
|
|
|
19) Drueke TB, Locatelli F, Clyne N, et al; CREATE investigators. Normalizaiton of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006; 355: 2071-84
|
|
|
|
|
|
20) FDA ALART [11/16/2006, Updated 2/16/2007 and 3/9/2007]: Information for healthcare professionals. Erythropoiesis stimulating agents(ESA)[Aranesp(darbepoetin), Epogen(epoetin alfa), and Procrit(epoetinalfa)] http://www.fda.gov/cder/drug/InfoSheets/HCP/RHE_HCP.htm
|
|
|
|
|
|
21) 鈴木正司, 斎藤 明, 下条文武, 他. 血液透析導入患者における患者背景と貧血治療の実態, 透析会誌. 2008; 41: 251-4
|
|
|
|
|
|
22) Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998; 339: 584-90
|
|
|
|
|
|
23) http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4315b1-01-FDA.pdf
|
|
|
|
|
|
24) Szczech LA, Barnhart HX, Inrig JK, et al. Secondary analysis of the CHOIR trial epoetin- dose and achieved hemoglobin outcomes. Kidney Int. 2008; 74: 791-8
|
|
|
|
|